Nuclear Medicine for the Delineation of Endocarditis
Abstract
Infective endocarditis (IE) is a serious disease caused by adherence of bacteria and platelets on the endocardium and heart valves. It may lead to persisting bacteraemia and serious complications, such as destruction of heart valves, congestive heart failure and septic embolism. In routine clinical practice, echocardiography is currently the standard imaging procedure for evaluation of possible endocarditis. The procedure is primarily indicated in patients with persisting bacteraemia in whom no focus of infection can be identified (Cheitlin et al. 1997). Since echocardiography may be false negative, the new Duke criteria — a classification system for patients suspected of endocarditis — were developed based on both clinical parameters and echocardiographic findings (Durack et al. 1994).
Keywords
Single Photon Emission Compute Tomography Heart Valve Infective Endocarditis Prosthetic Valve Single Photon Emission Compute Tomography ImagePreview
Unable to display preview. Download preview PDF.
References
- Cheitlin M.D., Alpert J.S., Armstrong W.F. (1997) ACC/AHA Guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 95: 1686-1744Google Scholar
- Durack D.T., Lukes A.S., Bright D.K. (1994) New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 96: 200-209Google Scholar
- Machac J, Vallabhajosula S, Goldman M.E., Goldsmith S.J., Palestro C, Strashun A, Vaquer R, Phillips R.A., Fuster V (1989) Value of blood-pool subtraction in cardiac indium-111labeled platelet imaging. J Nucl Med 30: 1445 - 1455PubMedGoogle Scholar
- Oyen W.I., Boerman O.C., Brouwers F.M. (2000) Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DMP444. Eur J Nucl Med 27: 392 - 399PubMedCrossRefGoogle Scholar